Highlights from Recent Cancer Literature

出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (23): 4301-4302
标识
DOI:10.1158/0008-5472.can-82-23-bi
摘要

Stimulator of interferon genes (STING) agonists rapidly moved into clinical trials with great optimism but have only shown mediocre therapeutic efficacy in patients. Li and colleagues revealed that STING activation in B cells drives immunosuppression that counteracts the stimulatory activity of these drugs, and that blocking regulatory B-cell function can improve STING-based cancer immunotherapy. Using specific deletion of STING (TMEM173) in B cells, they first showed that systemic delivery of STING agonists is more effective in controlling multiple cancer models, most importantly pancreatic ductal adenocarcinomas (PDAC). Next, they found that in response to STING activation, B cells take on a regulatory phenotype and produce two suppressive cytokines, IL35 and IL10. They found that IL35 production is essential for their suppressive nature, acting to suppress natural killer (NK) cell antitumor responses specifically in response to STING agonists. Finally, they showed that a combination of blocking anti-IL35 antibodies in combination with STING agonists leads to effective control of mouse models of PDAC and lung cancer and that PDAC patients, compared with healthy donors, exhibited elevated induction of IL35 in response to STING agonists.Expert Commentary: A combination of STING agonists with anti-IL35 blockade diminishes B-regulatory function and enhances NK-cell antitumor responses.Li S, Mirlekar B, Johnson BM, Brickey WJ, Wrobel JA, Yang N, et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 2022;610:373-80.Despite the key role of metastasis in cancer-related mortality, no recurrent metastasis-specific mutations have previously been identified. Rahrmann and colleagues discovered that the sodium leak channel nonselective protein (NALCN) is frequently mutated in cancer, leading to metastases. Pathogenic NALCN alterations were observed commonly in gastric, colorectal, lung, prostate, and head and neck cancers. Genetic or pharmacologic inhibition of NALCN led to increased circulating tumor cells and metastasis in multiple tumor types in vivo but did not modify primary tumor incidence or proliferation. Remarkably, NALCN inhibition increased normal epithelia cell shedding and led to the formation of ectopic structures in normal tissues.Expert Commentary: This study has identified the first recurrent metastasis-specific mutation and suggests a possible new pathway for targeting metastasis.Rahrmann EP, Shorthouse D, Jassim A, Hu LP, Ortiz M, Mahler-Araujo B, et al. The NALCN channel regulates metastasis and nonmalignant cell dissemination. Nature Genetics; Published September 29, 2022; doi: 10.1038/s41588-022-01182-0.CAR T therapy of acute myeloid leukemia (AML) remains challenging given significant overlap of target antigens with normal hematopoietic cells. Le and colleagues used xenotransplantation and an innovative ex vivo endothelial cell coculture system to model high-risk infant/childhood acute megakaryoblastic leukemia driven by the fusion oncoprotein CBFA2T3-GLIS2 (C/G). Interrogating transcriptomes of C/G cells, the authors identified six plasma membrane proteins in C/G leukemic cells that were silent in normal hematopoiesis. FOLR1 (folate receptor alpha) was prioritized as a known target in solid cancers. The authors developed a FOLR1-directed CAR T for C/G AML and showed that FOLR1 CAR T cells were effective at eliminating primary C/G-positive AML cells in vitro and in vivo. Further on-target and off-target evaluation is now warranted.Expert Commentary: Although FOLR1 is expressed in other healthy tissues, its absence from normal hemopoietic cells presents promise as a CAR T therapy in pediatric C/G AML, a subgroup with dismal prognosis.Le Q, Hadland B, Smith JL, Leonti A, Huang BJ, Ries R, et al. CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target. Journal of Clinical Investigation; Published September 22, 2022; doi: 10.1172/JCI157101.Neuroblastoma is a cold tumor, and immunotherapy has had little clinical success except for the use of anti-GD2 antibodies. Sengupta and colleagues analyzed transcripts involved in both immune activation as well as evasion by performing bulk single-cell RNA sequencing of human neuroblastoma tumors across multiple subtypes. After identifying a subset of immunogenic tumors, the authors performed further characterization and determined these tumors were more mesenchymal as compared with adrenergic. The authors also found that during the process of reprogramming between these lineages, the expression of immune genes was altered via epigenetic regulation. T-cell infiltration into the tumor was stimulated by cells expressing a mesenchymal signature, and checkpoint blockade immunotherapy was effective in inducing T-cell cytotoxicity against these mesenchymal tumors.Expert Commentary: This study describes differences in immunogenic potential between mesenchymal versus adrenergic neuroblastoma lineage, which dictates the efficacy of immunotherapy.Sengupta S, Das S, Crespo AC, Cornel AM, Patel AG, Mahadevan NR, et al. Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes. Nat Cancer 2022;3:1228-46.Despite advances in other tumor entities, immunotherapies have a limited effect in glioblastoma (GBM). A potential role of myeloid-derived suppressor cells (MDSC) in promoting treatment resistance suggests MDSCs as next-generation immunotherapy targets. MDSCs consist of two distinct subsets, granulocytic/polymorphonuclear (gMDSC) and monocytic (mMDSC). mMDSCs characteristically drive progression of GBM in preclinical models to a greater extent than gMDSCs. ATAC-seq performed on mMDSCs and gMDSCs isolated from the bone marrow of GL261-bearing or control mice indicated that mMDSCs and gMDSCs have distinct chromatin accessibility signatures. mMDSCs have higher integrin β1 and DPP-4 expression, which has functional consequences on the tumor-immune microenvironment. Blockade of integrin β1 abrogated the tumor-promoting phenotype of mMDSCs and altered the immune profile in the tumor microenvironment, while treatment with a DPP-4 inhibitor extended survival in preclinical GBM models.Expert Commentary: The current results demonstrate that integrin β1 and related DPP-4 signaling contribute to mMDSC function in GBM and highlight the potential of cell adhesion programming as a therapeutic target in GBM.Bayik D, Bartels CF, Lovrenert K, Watson DC, Zhang D, Kay K, et al. Distinct cell adhesion signature defines glioblastoma myeloid-derived suppressor cell subsets. Cancer Res 2022; 82:4274–87.The Hedgehog signaling pathway is central to proper patterning and proliferation in multiple developing tissues and persists in many adult stem cell types. Disruption of this pathway, often at the level of mutations in the membrane proteins PATCHED and SMOOTHENED, is seen in skin and brain tumors. However, how activation of SMOOTHENED leads to modulation of Hedgehog-dependent transcription factors is not fully understood. Using purified protein, cell-based systems, and model organisms, Happ and colleagues identified a sequence in the proximal C terminus of SMOOTHENED that interacted directly with PKA-C and acted as a pseudosubstrate. When SMOOTHENED was in its active conformation, this region inhibited PKA-C catalytic activity and thus freed GLI transcription factors from inhibitory phosphorylation, ultimately enabling Hedgehog-dependent transcriptional programs. Additional data suggests this “nonstandard” mechanism may also be at work downstream of another key morphogen, Wnt.Expert Commentary: Elucidation of the biochemical details of interactions between PKA-C and SMOOTHENED highlight a potential new point for pharmacological modulation of such pathways in the lab and clinic.Happ JT, Arveseth CD, Bruystens J, Bertinetti D, Nelson IB, Olivieri C, et al. A PKA inhibitor motif within SMOOTHENED controls Hedgehog signal transduction. Nature Struct Mol Biol 2022;29:990-9.Note: Breaking Insights are written by Cancer Research editors. Readers are encouraged to consult the articles referred to in each item for full details on the findings described.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
imfangyu完成签到,获得积分10
刚刚
花火花完成签到,获得积分10
1秒前
czj发布了新的文献求助10
1秒前
Polymer发布了新的文献求助10
1秒前
ysynqqr完成签到,获得积分10
1秒前
paofu发布了新的文献求助10
2秒前
3秒前
3秒前
小小浪味仙完成签到,获得积分20
4秒前
琪子完成签到,获得积分20
5秒前
6秒前
FashionBoy的应助被Syanx_8采纳,获得10
6秒前
6秒前
帝休完成签到,获得积分10
7秒前
汉堡包的应助被Polymer采纳,获得10
7秒前
秋风的应助被阿玉艳采纳,获得20
8秒前
ZHW完成签到,获得积分10
8秒前
调皮颜发布了新的文献求助10
9秒前
10秒前
997完成签到,获得积分10
10秒前
hhh的应助被成就书芹采纳,获得10
11秒前
观赏热带鱼完成签到,获得积分10
12秒前
zy发布了新的文献求助10
12秒前
kkkk完成签到,获得积分10
13秒前
我是老大的应助被Lz采纳,获得10
13秒前
雨雨雨发布了新的文献求助10
13秒前
排骨焖面完成签到,获得积分10
14秒前
mikro完成签到 ,获得积分10
15秒前
11完成签到,获得积分10
15秒前
宫水三叶完成签到,获得积分20
15秒前
GTCC完成签到,获得积分10
15秒前
乐乐的应助被李优秀采纳,获得10
16秒前
17秒前
丘比特的应助被FFFFFF采纳,获得10
18秒前
成就书芹完成签到,获得积分10
19秒前
鹿鹿七完成签到 ,获得积分10
19秒前
ning10完成签到,获得积分20
19秒前
李健的小迷弟的应助被琪子采纳,获得20
19秒前
玻丽露露完成签到,获得积分10
19秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186480
求助须知:如何正确求助?哪些是违规求助? 9574861
关于积分的说明 21838499
捐赠科研通 7784154
什么是DOI,文献DOI怎么找? 3434775
关于科研通互助平台的介绍 2559164
邀请新用户注册赠送积分活动 2481565